Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HF50 in advanced solid tumors
NCT07601334Phase 1Recruiting
- Sponsor
- HighField Biopharmaceuticals
- Start
- Sep 2026
- Primary completion
- Jun 2028
- Modality
- Antibody Conjugates, Small Molecules, Targeted Liposomes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of HF50 in solid tumor, sponsored by HighField Biopharmaceuticals. Primary endpoints: Dose Limiting Toxicities at 28 days, Adverse Events at 28 days and 1 more. Started Sep 2026; status: recruiting.
02
Drugs
HF50
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07601334.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07601334.